An update on arginine in sickle cell disease

References

• McGann PT, Nero AC, Ware RE. Clinical features of β-Thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:1–26.
   PubMedGoogle Scholar
• van Tuijn CFJ, Schimmel M, van Beers EJ, et al. Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study. Am J Hematol. 2017;92:E584–E590.
   PubMed Web of Science ®Google Scholar
• Blake A, Asnani V, Leger RR, et al. Stigma and illness uncertainty: adding to the burden of sickle cell disease. Hematology. 2018;23:122–130.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
   PubMed Web of Science ®Google Scholar
• Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018;8:CD012082.
   PubMedGoogle Scholar
• Tzounakas VL, Valsami SI, Kriebardis AG, et al. Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: current status, challenges and perspectives. Transfus Apher Sci. 2018;57:347–357.
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2018 Dec 1;380(2):121–131.
   PubMed Web of Science ®Google Scholar
• Yahouédéhou SCMA, Adorno EV, Da Guarda CC, et al. Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism. Pharmacogenomics J. 2018;18:730–739.
   PubMed Web of Science ®Google Scholar
• Ginwalla M, AlMasoud A, Tofovic D, et al. Cardiovascular evaluation and management of iron overload cardiomyopathy in sickle cell disease. Am J Hematol. 2018;93:E7–E9.
   PubMed Web of Science ®Google Scholar
• Yassin M, Soliman A, De Sanctis V, et al. Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): correlation with Serum Ferritin and Liver Enzymes Concentrations in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) Patients. Mediterr J Hematol Infect Dis. 2017;9:e2017037.
   PubMed Web of Science ®Google Scholar
• Lidonnici MR, Ferrari G. Gene therapy and gene editing strategies for hemoglobinopathies. Blood Cells Mol Dis. 2018;70:87–101.
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Truong TH, Saraf SL, et al. Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol. 2018;55:87–93.
   PubMed Web of Science ®Google Scholar
• Meier ER, Johnson T, Pinkney K, et al. Access to hematopoietic stem cell transplant for patients with sickle cell anemia. Pediatr Blood Cancer. 2018;65:e27105.
   PubMed Web of Science ®Google Scholar
• Sii-Felice K, Giorgi M, Leboulch P, et al. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. Exp Hematol. 2018;64:12–32.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127:750–760.
   PubMed Web of Science ®Google Scholar
• Helms CC, Gladwin MT, Kim-Shapiro DB. Erythrocytes and vascular function: oxygen and nitric oxide. Front Physiol. 2018;9:125.
   PubMed Web of Science ®Google Scholar
• Collins JA, Rudenski A, Gibson J, et al. Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve. Breathe (Sheff). 2015;11:194–201.
   PubMedGoogle Scholar
• Franco-Obregón A, Ureña J, López-Barneo J. Oxygen-sensitive calcium channels in vascular smooth muscle and their possible role in hypoxic arterial relaxation. Proc Natl Acad Sci USA. 1995;92:4715–4719.
   PubMed Web of Science ®Google Scholar
• Jackson WF. Arteriolar oxygen reactivity: where is the sensor and what is the mechanism of action? J Physiol. 2016;594:5055–5077.
   PubMed Web of Science ®Google Scholar
• Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376.
   PubMed Web of Science ®Google Scholar
• Stuehr DJ, Haque MM. Nitric oxide synthase enzymology in the 20 years after the Nobel Prize. Br J Pharmacol. 2018 Nov 6. DOI:10.1111/bph.14533.
   PubMed Web of Science ®Google Scholar
• Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem. 1981;14:351–358.
   PubMed Web of Science ®Google Scholar
• Herold S, Exner M, Nauser T. Kinetic and mechanistic studies of the NO center dot-mediated oxidation of oxymyoglobin and oxyhemoglobin. Biochemistry. 2001;40:3385–3395.
   PubMed Web of Science ®Google Scholar
• Liu X, Miller MJS, Joshi MS, et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709–18713.
   PubMed Web of Science ®Google Scholar
• Vaughn MW, Huang KT, Kuo L, et al. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem. 2000;275:2342–2348.
   PubMed Web of Science ®Google Scholar
• Liao JC, Hein WT, Vaughn MW, et al. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci USA. 1999;96:8757–8761.
   PubMed Web of Science ®Google Scholar
• Schnog JB, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371–375.
   PubMed Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cellfree hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–1389.
   PubMed Web of Science ®Google Scholar
• Antwi-Boasiako C, Campbell AD. Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana. Vasc Health Risk Manag. 2018;14:199–204.
   PubMed Web of Science ®Google Scholar
• Lopez BL, Davis-Moon L, Ballas SK, et al. Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. Am J Hematol. 2000;64:15–19.
   PubMed Web of Science ®Google Scholar
• Satitthummanid S, Uaprasert N, Songmuang SB, et al. Depleted nitric oxide and prostaglandin E2 levels are correlated with endothelial dysfunction in β-thalassemia/HbE patients. Int J Hematol. 2017;106:366–374.
   PubMed Web of Science ®Google Scholar
• Zennadi R, Whalen EJ, Soderblom EJ, et al. Erythrocyte plasma membranebound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood. 2012;119:1217–1227.
   PubMed Web of Science ®Google Scholar
• Hierso R, Waltz X, Mora P, et al. Effects of oxidative stress on red blood cell rheology in sickle cell patients. Br J Haematol. 2014;166:601–606.
   PubMed Web of Science ®Google Scholar
• Donadee C, Raat NJ, Kanias T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124:465–476.
   PubMed Web of Science ®Google Scholar
• Merle NS, Grunenwald A, Rajaratnam H, et al. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018. 3(12). pii: 96910.
   Web of Science ®Google Scholar
• Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler Thromb Vasc Biol. 2014;34:313–320.
   PubMed Web of Science ®Google Scholar
• Voskou S, Aslan M, Fanis P, et al. Oxidative stress in β-thalassaemia and sickle cell disease. Redox Biol. 2015;6:226–239.
   PubMed Web of Science ®Google Scholar
• Biswal S, Rizwan H, Pal S, et al. Oxidative stress, antioxidant capacity, biomolecule damage, and inflammation symptoms of sickle cell disease in children. Hematology. 2018;24:1–9.
   PubMed Web of Science ®Google Scholar
• Jana S, Meng F, Hirsch RE, et al. Oxidized mutant human hemoglobins S and E induce oxidative stress and bioenergetic dysfunction in human pulmonary endothelial cells. Front Physiol. 2017;8:108.
   PubMed Web of Science ®Google Scholar
• Hannemann A, Rees DC, Brewin JN, et al. Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cellanaemia. Br J Haematol. 2018;182:567–578.
   PubMed Web of Science ®Google Scholar
• Jia Y, Buehler PW, Boykins RA, et al. Structural basis of peroxide-mediated changes in human hemoglobin: a novel oxidative pathway. J Biol Chem. 2007;282:4894–4907.
   PubMed Web of Science ®Google Scholar
• Vasconcellos LR, Dutra FF, Siqueira MS, et al. Protein aggregation as a cellular response to oxidative stress induced by heme and iron. Proc Natl Acad Sci USA. 2016;113:E7474–E7482.
   PubMed Web of Science ®Google Scholar
• Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterindependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest. 2003;112:725–735.
   PubMed Web of Science ®Google Scholar
• Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424.
   PubMed Web of Science ®Google Scholar
• Landburg PP, Tdeerlink T, Biemond BJ, et al. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis. 2010;44:229–232.
   PubMed Web of Science ®Google Scholar
• Boger RH, Maas R, Schulze F, et al. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009;60:481–487.
   PubMed Web of Science ®Google Scholar
• Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279–2285.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
   PubMed Web of Science ®Google Scholar
• Popolo A, Adesso S, Pinto A, et al. L-Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids. 2014;46:2271–2286.
   PubMed Web of Science ®Google Scholar
• Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1–17.
   PubMed Web of Science ®Google Scholar
• Phang JM, Liu W, Hancock C, et al. The proline regulatory axis and cancer. Front Oncol. 2012 21;2:60.
   PubMedGoogle Scholar
• Luiking YC, Ten Have GA, Rr W, et al. Arginine de novo and nitric oxide production in disease states. Am J Physiol Endocrinol Metab. 2012;303:E1177–E1189.
   PubMed Web of Science ®Google Scholar
• Sibal L, Agarwal SC, Home PD, et al. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Ver. 2010;6:82–90.
   PubMedGoogle Scholar
• Aliev G, Palacios HH, Lipsitt AE, et al. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res. 2009;16:293–305.
   PubMed Web of Science ®Google Scholar
• Luiking YC, Poeze M, Ramsay G, et al. Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production. Am J Clin Nutr. 2009;89:142–152.
   PubMed Web of Science ®Google Scholar
• Nakae H, Endo S, Kikuchi M, et al. Nitrite/nitrate (NOx) levels and hemodynamics during septic shock. Surg Today. 2000;30:683–688.
   PubMed Web of Science ®Google Scholar
• Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci. 1990;300:366–371.
   PubMed Web of Science ®Google Scholar
• Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81–90.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Wang Z, Cho L, et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009;53:2061–2067.
   PubMed Web of Science ®Google Scholar
• Cox SE, Makani J, Komba AN, et al. Global arginine bioavailability in Tanzanian sickle cell anemia patients at steady-state: a nested case control study of deaths versus survivors. Br J Haematol. 2011;155:522–524.
   PubMed Web of Science ®Google Scholar
• Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000;22:515–520.
   PubMed Web of Science ®Google Scholar
• Enwonwu CO. Increased metabolic demand for arginine in sickle cell anemia. Med Sci Res. 1989;17:997–998.
   Google Scholar
• Lopez BL, Kreshak AA, Morris CR, et al. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol. 2003;120:532–534.
   PubMed Web of Science ®Google Scholar
• Schnog JB, Teerlink T, van der Dijs FP, et al. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol. 2005;84:282–286.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Wang Z, Machado RF, et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol. 2009;145:506–513.
   PubMed Web of Science ®Google Scholar
• Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood. 1980;55:649.
   PubMed Web of Science ®Google Scholar
• Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651–4655.
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:801–809.
   PubMed Web of Science ®Google Scholar
• Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997;87:988–990.
   PubMed Web of Science ®Google Scholar
• Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med. 1999;27:2563–2568.
   PubMed Web of Science ®Google Scholar
• Montero-Huerta P, Hess DR, Head CA. Inhaled nitric oxide for treatment of sickle cell stroke. Anesthesiology. 2006;105:619–621.
   PubMed Web of Science ®Google Scholar
• Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003;289:1136–1142.
   PubMed Web of Science ®Google Scholar
• Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85:800–802.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305:893–902.
   PubMed Web of Science ®Google Scholar
• Maitre B, Djibre M, Katsahian S, et al. Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study. Intensive Care Med. 2015;41:2121–2129.
   PubMed Web of Science ®Google Scholar
• Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445–453.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Anele UA, Trueheart IN, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–668.
   PubMed Web of Science ®Google Scholar
• Romero JR, Suzuka SM, Nagel RL, et al. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99:1103–1108.
   PubMed Web of Science ®Google Scholar
• Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41:1771–1780.
   PubMed Web of Science ®Google Scholar
• Kehinde MO, Ogungbemi SI, Anigbogu CN, et al. l-Arginine supplementation enhances antioxidant activity and erythrocyte integrity in sickle cell anaemia subjects. Pathophysiology. 2015;22:137–142.
   PubMedGoogle Scholar
• Jaja SI, Ogungbemi SO, Kehinde MO, et al. Supplementation with l-arginine stabilizes plasma arginine and nitric oxide metabolites, suppresses elevated liver enzymes and peroxidation in sickle cell anaemia. Pathophysiology. 2016;23:81–85.
   PubMedGoogle Scholar
• Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111:498–500.
   PubMed Web of Science ®Google Scholar
• Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sicklecell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98:1375–1382.
   PubMed Web of Science ®Google Scholar
• Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003 Jul 1;168:63–69.
   PubMed Web of Science ®Google Scholar
• Elias DB, Barbosa MC, Rocha LB, et al. L-arginine as an adjuvant drug in the treatment of sickle cell anaemia. Br J Haematol. 2013;160:410–412.
   PubMed Web of Science ®Google Scholar
• Baliga BS, Haynes J Jr, Obiako B, et al. Combined effects of arginine and hydroxyurea on BFU-E derived colony growth and HbF synthesis in erythroid progenitors isolated from sickle cell blood. Cell Mol Biol (Noisy-Le-Grand). 2010;56(Suppl):OL1290–OL1298.
   PubMedGoogle Scholar
• Vilas-Boas W, Cerqueira BA, Zanette AM, et al. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Hematol. 2010;89:877–882.
   PubMed Web of Science ®Google Scholar
• Steppan J, Tran HT, Bead VR, et al. Arginase inhibition reverses endothelial dysfunction, pulmonary hypertension, and vascular stiffness in transgenic sickle cell mice. Anesth Analg. 2016;123:652–658.
   PubMed Web of Science ®Google Scholar
• Iyamu EW, Ekekezie C, Woods GM. In vitro evidence of the inhibitory capacity of chloroquine on arginase activity in sickle erythrocytes. Br J Haematol. 2007;139:337–343.
   PubMed Web of Science ®Google Scholar
• Wijnands KA, Meesters DM, van Barneveld KW, et al. Citrulline supplementation improves organ perfusion and arginine availability under conditions with enhanced arginase activity. Nutrients. 2015 Jun 29;7:5217–5238.
   PubMed Web of Science ®Google Scholar
• Waugh WH, Daeschner CW, Files BA, et al. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results. J Natl Med Assoc. 2001;93:363–371.
   PubMed Web of Science ®Google Scholar
• Marealle AI, Siervo M, Wassel S, et al. A pilot study of a non-invasive oral nitrate stable isotopic method suggests that arginine and citrulline supplementation increases whole-body NO production in Tanzanian children with sicklecell disease. Nitric Oxide. 2018;74:19–22.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018;379:226–235.
   PubMed Web of Science ®Google Scholar
• Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25:629–634.
   PubMed Web of Science ®Google Scholar
• McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol. 2010;151:516–524.
   PubMed Web of Science ®Google Scholar
• Monti LD, Galluccio E, Fontana B, et al. Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: post hoc analysis of the L-arginine trial. Metabolism. 2015;64:1582–1591.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011;153:655–663.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Jacob E, Styles L, et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017;177:620–629.
   PubMed Web of Science ®Google Scholar
• Moreira JA, Machado RP, Laurentino MR, et al. Influence of βS-Globin haplotypes and hydroxyurea on arginase i levels in sickle cell disease. Dis Markers. 2016;2016:9172726.
   PubMedGoogle Scholar